fashion -WSS

fashion

author：fashion 2025-09-06 03:32:59 - browse：728

A purple number 3 with an eye is surrounded by smaller, black number 3s on a green background — 3 to watch coverage from STAT — Christine Kao/STAT

Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather for the J.P. Morgan Healthcare Conference to pick apart the year that was and prognosticate about the one to come. The consensus, in good markets and bad, is almost always cautious optimism for boom times ahead, a prediction that in recent years has had groundhog-level accuracy.

But after two years of steady decline, 2024 might finally prove them right. Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, the advance of cutting-edge technologies, and a few reminders that big drug companies are still willing to pay billions of dollars for small ones.

Here are three major themes that we expect to drive the news in 2024 and determine whether biotech’s comeback is a sustainable trend or an interest-rate phenomenon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Eli Lilly to pay $200M for Beam’s stake in gene

WSS

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Chimpanzees, like humans and whales, get menopause: Study

Emergency medicine has repudiated 'excited delirium.' Now what?

CDC recommends rationing of RSV shot due to shortages

Readout Newsletter: XBI biotech index, Akero Therapeutics

WHO may add ‘noma' to its list of neglected tropical diseases

leisure time

fashion

focus

Activists slam private health insurers over coverage restrictions

CDC recommends rationing of RSV shot due to shortages

Guidelines to prevent youth baseball injuries need more muscle

Nonprofit, backed by Microsoft, to certify AI tools in health care

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Drug repurposing or repositioning? The language matters

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

explore

Emergency medicine has repudiated 'excited delirium.' Now what?

Hospital chaplains balance Covid safety with patients’ spiritual needs

FDA early review: GLP

The pink breast cancer awareness ribbon needs a redesign

Ascension's ugly legal battle over care for poor patients in Texas

Gene therapy denied for Afghan refugee whose father aided U.S.

knowledge

hotspot

focus

hotspot